Literature DB >> 23168710

Resistance to ceftriaxone in Vibrio cholerae.

Jharna Mandal, V Preethi, R Vasanthraja, S Srinivasan, Subhash Chandra Parija.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168710      PMCID: PMC3516037     

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
Sir, Cholera characterized by rice water stools is more common in developing countries due to poor sanitation and improperly protected water supply1. As with most enteric pathogens cholera can be controlled by rehydration alone but antimicrobials are indicated in severe cases and also to reduce the course of disease. Spread of cholera epidemics has been associated with emergence of drug resistant strains2. The current therapy for cholera as indicated by the World Health Organization3 primarily involves tetracycline and ciprofloxacin. Drug resistance in bacterial pathogens has increased at an alarming rate over the last few decades. Progressive drug resistance in Vibrio cholerae has been noted as evident from the available literature4–8. Though the use of a third generation cephalosporin is not yet recommended for the treatment of cholera, but the appearance of resistance to this group of antimicrobials is quite alarming910. Here, we report the resistance to ceftriaxone, a third generation cephalosporin, in V. cholerae isolates from three paediatrics cases. The three cases (age range two boys of 1 and 4 yr and one 2 yr girl) had reported to the department of Pediatrics between the months of June and August 2010 at Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, with history of passing loose, watery stools (>9-10 time in a day) and were provisionally diagnosed to be suffering from cholera. The cases reported to the hospital on different months, independent of each other. Also, they did not belong to the same locality and were unrelated. The stool samples were inoculated onto MacConkey agar and thiosulphate citrate bile-salt sucrose (TCBS) agar (Hi-media, Mumbai). Enrichment was provided with alkaline peptone water, subculture from which was done after 6 h of incubation at 37°C onto MacConkey agar and TCBS agar. Suspected colonies were identified as V. cholerae by the standard biochemical tests1112, the serogroup was confirmed by agglutination with specific antiserum (BD Difco™, Becton Dickinson, USA). Antibiotic susceptibility was determined by the Kirby-Bauer method as per Clinical Laboratory Standards Institute guidelines (CLSI)13, which showed that this isolate was resistant to ampicillin (10 μg), ceftriaxone (30 μg), co-trimoxazole (25 μg) and sensitive only to ciprofloxacin (5 μg) and tetracycline (30 μg). All the three children were treated with ciprofloxacin. The three isolates were subjected to the agar dilution test and E test (BioMérieux, Sweden) for the determination of the minimum inhibitory concentration (MIC) of ceftriaxone. For the agar dilution method, ceftriaxone-sodium salt (Hi-media, Mumbai, India) and Mueller-Hinton (M-H) agar (Hi-media, Mumbai, India) were used. The drug was reconstituted in sterile distilled water (as described by the manufacturer), was stored at 4°C and used within 2 days of reconstitution. Different dilutions of the drug were used starting from 0.5 to 128 μg/ml. For growth controls, plates containing drug free agar were also prepared. The MIC was performed as per recommendations13. ATCC Escherichia coli 25922 was inoculated on each plate as growth control. To check for viability of each test isolate and also as an added check for purity, control plates that did not contain drugs were inoculated last. Inoculated plates were allowed to stand for several minutes until the inoculum drops had been completely absorbed by the medium; then the plates were inverted and incubated at 37°C for 20 h before the results were read. The E-test was carried out as per the manufacturer's instructions. The strips containing the antibiotics were applied with sterile forceps and incubated at 37°C overnight. Tear drop shaped zone of inhibition was observed in all three agar plates. MIC was read as the value on the E strip where the two arms of the ellipse met. According to the CLSI13, the breakpoints for MIC of cefrtiaxone are sensitive (<1 μg/ml), intermediate resistant (2 μg/ml) and resistant (>4 μg/ml). The MIC of the three V. cholerae isolates was 16 μg/ml, by the agar dilution method as well as the E test method, which indicated resistance to ceftriaxone. The double disk synergy test was performed as described earlier14 which was negative. As the genetic analysis of these isolates could not be done, therefore the mechanisms mediating the reduced susceptibility of these isolates to ceftriaxone is not yet clear. Increase in antimicrobial resistance in enteric pathogens is especially important in developing countries where diarrhoea is common. Globally, many strains of V. cholerae have shown resistance to commonly used antibiotics including tetracycline, co-trimoxazole, ampicllin, chloramphenicol and nalidixic acid10 but have largely remained susceptible to the third generation cephalosporins. Resistance to cephalosporins was first documented in Argentina10 where the MIC of ceftazidime was determined to be 64 μg/ml. The detection of resistance to ceftriaxone in V. cholerae is a matter of concern, considering the epidemic potential of the organism. Excessive use and misuse of antimicrobials can create an effective selection pressure on microbes which in turn can develop mechanisms to render these antimicrobials ineffective. There is a need to monitor the resistance pattern of this organism and also the use of antimicrobials in its control.
  11 in total

1.  In vitro susceptibility of Vibrio cholerae O1 biotype El Tor strains associated with an outbreak of cholera in Kerala, Southern India.

Authors:  F Sabeena; G Thirivikramji; G Radhakutty; P Indu; D V Singh
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

2.  Plasmidic extended-spectrum beta-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina.

Authors:  Alejandro Petroni; Alejandra Corso; Roberto Melano; María Luisa Cacace; Ana María Bru; Alicia Rossi; Marcelo Galas
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India.

Authors:  P Garg; S Sinha; R Chakraborty; S K Bhattacharya; G B Nair; T Ramamurthy; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.

Authors:  James H Jorgensen; Janet F Hindler
Journal:  Clin Infect Dis       Date:  2006-12-07       Impact factor: 9.079

5.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

6.  Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia.

Authors:  Periska Tjaniadi; Murad Lesmana; Decy Subekti; Nunung Machpud; Shinta Komalarini; Wasis Santoso; Cyrus H Simanjuntak; Narain Punjabi; James R Campbell; William K Alexander; H James Beecham; Andrew L Corwin; Buhari A Oyofo
Journal:  Am J Trop Med Hyg       Date:  2003-06       Impact factor: 2.345

7.  Emergence of tetracycline-resistant Vibrio cholerae O1 serotype Inaba, in Kolkata, India.

Authors:  Amit Roychowdhury; Arpita Pan; Dharitri Dutta; Asish Kumar Mukhopadhyay; T Ramamurthy; Ranjan Kumar Nandy; Sujit Kumar Bhattacharya; Mihir Kumar Bhattacharya
Journal:  Jpn J Infect Dis       Date:  2008-03       Impact factor: 1.362

8.  Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India.

Authors:  Jagdish Chander; Neelam Kaistha; Varsha Gupta; Manjula Mehta; Nidhi Singla; Antariksh Deep; B L Sarkar
Journal:  Indian J Med Res       Date:  2009-05       Impact factor: 2.375

9.  Changing profile of Vibrio cholerae O1, O139 in Delhi & its periphery (2003-2005).

Authors:  N C Sharma; P K Mandal; Rohini Dhillon; Madhu Jain
Journal:  Indian J Med Res       Date:  2007-05       Impact factor: 2.375

10.  Antimicrobial resistance of Vibrio cholerae O1 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique.

Authors:  Inácio Mandomando; Mateu Espasa; Xavier Vallès; Jahit Sacarlal; Betuel Sigaúque; Joaquim Ruiz; Pedro Alonso
Journal:  J Antimicrob Chemother       Date:  2007-07-11       Impact factor: 5.790

View more
  2 in total

1.  Twin outbreak of cholera in rural North Karnataka, India.

Authors:  Shuchismita Dey; Mahantesh V Parande; Aisha M Parande; S L Lakkannavar; Poonam K Rathore; B G Mantur; Sanjiva D Kholkute; Subarna Roy
Journal:  Indian J Med Res       Date:  2014-09       Impact factor: 2.375

2.  Reduced Susceptibility to Extended-Spectrum β-Lactams in Vibrio cholerae Isolated in Bangladesh.

Authors:  Daniela Ceccarelli; Munirul Alam; Anwar Huq; Rita R Colwell
Journal:  Front Public Health       Date:  2016-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.